| $337M | ||
| $259M | ||
| $79M | ||
| $60M | ||
| $58M | ||
| $50M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Over the last 12 months, insiders at Bone Biologics Corporation have bought $0 and sold $0 worth of Bone Biologics Corporation stock.
On average, over the past 5 years, insiders at Bone Biologics Corporation have bought $21,637 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 8,000 shares for transaction amount of $5,120 was made by Walsh Deina H (Chief Financial Officer) on 2023‑09‑13.
| 2023-09-13 | Walsh Deina H | Chief Financial Officer | 8,000 0.2552% | $0.64 | $5,120 | -55.66% | ||
| 2023-09-11 | Frelick Jeff | Chief Executive Officer | 9,500 0.311% | $0.69 | $6,530 | -55.50% | ||
| 2023-09-06 | Walsh Deina H | Chief Financial Officer | 7,000 0.219% | $0.71 | $4,967 | -58.20% | ||
| 2023-08-31 | Frelick Jeff | Chief Executive Officer | 7,600 0.2366% | $0.66 | $5,020 | -54.06% | ||
| 2020-01-02 | Hankey Don | Chairman of the Board | 195,000 1.6745% | $1.00 | $195,000 | +238663.11% | ||
| 2020-01-02 | Hankey Bret | director | 195,000 1.6745% | $1.00 | $195,000 | +238663.11% | ||
| 2019-08-06 | Hankey Don | Chairman of the Board | 553,191 – | $0 | $0 | |||
| 2019-08-06 | Hankey Bret | director | 553,191 – | $0 | $0 | |||
| 2019-07-15 | Hankey Don | Chairman of the Board | 85,106 – | $0 | $0 | |||
| 2019-07-15 | Hankey Bret | director | 85,106 – | $0 | $0 | |||
| 2019-06-20 | Hankey Bret | director | 1.06M – | $0 | $0 | |||
| 2019-06-20 | Hankey Don | Chairman of the Board | 1.06M – | $0 | $0 | |||
| 2019-05-07 | Hankey Don | Chairman of the Board | 1.06M – | $0 | $0 | |||
| 2019-05-07 | Hankey Bret | director | 1.06M – | $0 | $0 | |||
| 2019-03-25 | Hankey Don | Chairman of the Board | 1.49M – | $0 | $0 | |||
| 2019-03-25 | Hankey Bret | director | 1.49M – | $0 | $0 | |||
| 2018-12-17 | Hankey Don | Chairman of the Board | 18.01M – | $0 | $0 | |||
| 2018-12-17 | Hankey Bret | director | 18.01M – | $0 | $0 | |||
| 2016-02-29 | MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. | 10 percent owner | 731,707 23.9735% | $2.05 | $1.5M | |||
| 2015-12-22 | Sale | SOO B CHIA | director | 5,274 0.1332% | $1.58 | $8,333 |
| Hankey Don | Chairman of the Board | 28563398 5239.3272% | $151.39M | 7 | 0 | |
| Hankey Bret | director | 28122518 5158.4574% | $149.05M | 7 | 0 | |
| MUSCULOSKELETAL TRANSPLANT FOUNDATION, INC. | 10 percent owner | 11640096 2135.1196% | $61.69M | 1 | 1 | |
| AFH Holding & Advisory, LLC | 10 percent owner | 3385358 620.9695% | $17.94M | 0 | 3 | |
| SOO B CHIA | director | 2982804 547.1298% | $15.81M | 0 | 2 | |
| WU BENJAMIN | director | 970991 178.1069% | $5.15M | 0 | 2 | |
| Frelick Jeff | Chief Executive Officer | 17204 3.1557% | $91,181.20 | 2 | 0 | <0.0001% |
| Walsh Deina H | Chief Financial Officer | 15000 2.7514% | $79,500.00 | 2 | 0 | <0.0001% |
$1,105,104 | 34 | -11.40% | $317.98M | |
$4,857,655 | 34 | -32.19% | $5.42M | |
$167,957 | 12 | -9.47% | $68.13M | |
$58,022,364 | 11 | 36.96% | $256.09M | |
$24,971 | 6 | -37.72% | $54.07M | |
Bone Biologics Corporation (BBLG) | $21,637 | 4 | -55.86% | $2.89M |
$12,661,990 | 3 | 81.20% | $29.86M | |
$49,600 | 2 | -57.41% | $11.78M | |
$9,786 | 2 | -56.58% | $4.11M | |
$13,650 | 1 | -48.97% | $6.69M | |
$1,149 | 1 | 69.23% | $19.51M |
| Increased Positions | 2 | +25% | 1,476 | +14.7% |
| Decreased Positions | 4 | -50% | 7,173 | -71.45% |
| New Positions | 0 | New | 0 | New |
| Sold Out Positions | 3 | Sold Out | 6,912 | Sold Out |
| Total Postitions | 6 | -25% | 4,342 | -56.75% |
| Ubs Group Ag | $16.00 | 0.73% | 21,866 | -10,985 | -33.44% | 2024-12-31 |
| Geode Capital Management, Llc | $11.00 | 0.51% | 15,355 | +15,355 | New | 2024-12-31 |
| Hrt Financial Lp | $11.00 | 0.49% | 14,658 | -7,618 | -34.2% | 2024-12-31 |
| Citigroup Inc | $4.00 | 0.17% | 4,948 | +4,948 | New | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $2.00 | 0.11% | 3,387 | +1,601 | +89.64% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 20 | +6 | +42.86% | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | 0% | 1 | 0 | 0% | 2025-03-31 |
| Morgan Stanley | $0 | 0% | 0 | -28,527 | Sold Out | 2024-12-31 |